{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:57:44Z","timestamp":1792457864419,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10072-026-09044-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:35:30Z","timestamp":1776735330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhaled levodopa in Parkinson\u00b4s disease with motor fluctuations: post-commercialization experience in two movement disorders units"],"prefix":"10.1007","volume":"47","author":[{"given":"Pablo","family":"Ros-Arlanz\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Valverde-Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luisa","family":"Almarcha-Menargues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Pati\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Alonso-C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"P\u00e9rez-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Send\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Fanjul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica M.","family":"Kurtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Mart\u00ednez-Castrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6873-4823","authenticated-orcid":false,"given":"Isabel","family":"Pare\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"9044_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mds.26122","volume":"30","author":"S Fahn","year":"2015","unstructured":"Fahn S, Poewe W (2015) Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord 30:1\u20133. https:\/\/doi.org\/10.1002\/mds.26122","journal-title":"Mov Disord"},{"key":"9044_CR2","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/brain\/awaa181","volume":"143","author":"R Cilia","year":"2020","unstructured":"Cilia R, Cereda E, Akpalu A et al (2020) Natural history of motor symptoms in Parkinson\u2019s disease and the long-duration response to levodopa. Brain 143:2490\u20132501. https:\/\/doi.org\/10.1093\/brain\/awaa181","journal-title":"Brain"},{"key":"9044_CR3","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Hauser RA, Grosset DG et al (2016) A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord 31:1356\u20131365. https:\/\/doi.org\/10.1002\/mds.26611","journal-title":"Mov Disord"},{"key":"9044_CR4","doi-asserted-by":"publisher","unstructured":"Lipp MM, Batycky R, Moore J et al (2016) Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med 8. https:\/\/doi.org\/10.1126\/scitranslmed.aad8858","DOI":"10.1126\/scitranslmed.aad8858"},{"key":"9044_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hauser RA, Pahwa R et al (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145\u2013154. https:\/\/doi.org\/10.1016\/S1474-4422(18)30405-8","journal-title":"Lancet Neurol"},{"key":"9044_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.parkreldis.2019.03.026","volume":"64","author":"RA Hauser","year":"2019","unstructured":"Hauser RA, Isaacson SH, Ellenbogen A et al (2019) Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson\u2019s disease. Parkinsonism Relat Disord 64:175\u2013180. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.03.026","journal-title":"Parkinsonism Relat Disord"},{"key":"9044_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","volume":"71","author":"DG Grosset","year":"2020","unstructured":"Grosset DG, Dhall R, Gurevich T et al (2020) Inhaled levodopa in Parkinson\u2019s disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord 71:4\u201310. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.012","journal-title":"Parkinsonism Relat Disord"},{"key":"9044_CR8","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/mds.28726","volume":"36","author":"CW Olanow","year":"2021","unstructured":"Olanow CW, Poewe W, Rascol O, Stocchi F (2021) On-Demand Therapy for OFF Episodes in Parkinson\u2019s Disease. Mov Disord 36:2244\u20132253. https:\/\/doi.org\/10.1002\/mds.28726","journal-title":"Mov Disord"},{"key":"9044_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1212\/CPJ.0000000000001143","volume":"12","author":"G Glenardi","year":"2022","unstructured":"Glenardi G, Handayani T, Barus J, Mangkuliguna G (2022) Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Neurol Clin Pract 12:139\u2013148. https:\/\/doi.org\/10.1212\/CPJ.0000000000001143","journal-title":"Neurol Clin Pract"},{"key":"9044_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/mds.22898","volume":"25","author":"AH Evans","year":"2010","unstructured":"Evans AH, Lawrence AD, Cresswell SA et al (2010) Compulsive use of dopaminergic drug therapy in Parkinson\u2019s disease: Reward and anti-reward. Mov Disord 25:867\u2013876. https:\/\/doi.org\/10.1002\/mds.22898","journal-title":"Mov Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09044-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:31:11Z","timestamp":1778308271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09044-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["9044"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09044-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that the study was approved by the Ethics Committee of Hospital Ram\u00f3n y Cajal (approval number 038\/24), and that approval was also obtained from the institutional review board of Hospital Ruber Internacional. Informed consent was not required due to the retrospective nature of the study. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"PRA has received honoraria as a speaker at scientific meetings from Bial, and travel support for scientific meetings from Esteve, UCB, Ever-Pharma, and Merz.PRA has received honoraria as a speaker at scientific meetings from Bial, and travel support for scientific meetings from Esteve, UCB, Ever-Pharma, and Merz.MAM has received travel support for scientific meetings from Zambon and a Horizon Europe research grant.AAC has received honoraria as a speaker from Ipsen, Stada, Italfarmaco, Zambon, and Bial, and travel grants from AbbVie and Bial.PPT has received honoraria from Krka, Stada, Alter, and Biogen.JLS has received honoraria for advisory services from Biogen, and for scientific presentations from the Spanish Neurological Society.MMK has received honoraria from Eisai, Bial, Esteve, and the Spanish Neurological Society; consulting fees from Bial; and research grants from Horizon Europe and Quironsalud.JMC has received honoraria as a speaker from AbbVie, Allergan, Bial, Boehringer, GSK, Krka, Merz, Ipsen, Italfarmaco, Lundbeck, Medtronic, Teva, UCB, and Zambon; travel grants from AbbVie, Allergan, Bial, Italfarmaco, Teva, UCB, Merz, Krka, and Zambon; research grants from AbbVie, Allergan, Merz, Italfarmaco, Lundbeck, UCB, and Zambon; and has participated in advisory boards for AbbVie, Allergan, GSK, Bial, Merz, Merck, Boehringer, Ipsen, Italfarmaco, Lundbeck, Orion, UCB, and Zambon.IP has received honoraria as a speaker at scientific meetings from Zambon, Bial, AbbVie, and the Spanish Neurological Society, and travel support for scientific meetings from Esteve.NVM, AP, and SF declare no financial disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"445"}}